金沙集团1862cc(股份)有限公司-baidu百科

2025-08-26

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

查看详情

02-012024

Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026, a Monoclonal Antibody Targeting OX40, in Patients with Moderate to Severe Atopic Dermatitis

Guangzhou, China -- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline o...
01-032024

Bio-Thera Solutions Partners with Macter International to Market BAT1706, an Avastin®1 biosimilar, in Pakistan and Afghanistan

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline ...
12-082023

FDA Approves Bio-Thera Solutions’ Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®

Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United StatesAvzivi® is the second biosimilar...